A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation

CD40 agonism by systemic administration of CD40 monoclonal antibodies has been explored in clinical trials for immunotherapy of cancer, uncovering enormous potential, but also dosing challenges in terms of systemic toxicity. CD40-dependent activation of antigen presenting cells is dependent on cross...

Descripción completa

Detalles Bibliográficos
Autores principales: Mega, Alessandro, Mebrahtu, Aman, Aniander, Gustav, Ryer, Eva, Sköld, Annette, Sandegren, Anna, Backström Rydin, Eva, Rockberg, Johan, Östman, Arne, Frejd, Fredrik Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332328/
https://www.ncbi.nlm.nih.gov/pubmed/37332119
http://dx.doi.org/10.1080/19420862.2023.2223750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332328/
https://www.ncbi.nlm.nih.gov/pubmed/37332119
http://dx.doi.org/10.1080/19420862.2023.2223750

Ejemplares similares